# MPL

## Overview
The MPL gene encodes the thrombopoietin receptor, a transmembrane protein that plays a pivotal role in hematopoiesis by regulating platelet production. The protein product, also known as CD110, is a member of the cytokine receptor family and functions as a homodimeric receptor upon binding with its ligand, thrombopoietin (Tpo). This interaction is crucial for activating downstream signaling pathways, including the JAK/STAT, MAPK/ERK, and PI3K/AKT pathways, which are essential for cell proliferation, differentiation, and survival (KAUSHANSKY2009Molecular; Varghese2017The). Mutations in the MPL gene can lead to constitutive activation of these pathways, contributing to various hematological disorders, such as myeloproliferative neoplasms and congenital amegakaryocytic thrombocytopenia (Chaligné2007Evidence; He2013Different). The receptor's structure, characterized by cytokine receptor homology regions and a transmembrane domain, is integral to its function and regulation, making it a significant focus of research in understanding and treating hematopoietic diseases (Sarson-Lawrence2024Cryo-EM; Alnakhle2023In).

## Structure
The MPL gene encodes the thrombopoietin receptor, a critical component in hematopoiesis. The protein product, known as CD110, consists of 635 amino acids and includes several distinct structural features. The primary structure of MPL is organized into 12 exons, with specific exons encoding the cytokine receptor domains, transmembrane region, and cytoplasmic domain (Alnakhle2023In).

The secondary structure of MPL includes two cytokine receptor homology regions (CHRs) in its extracellular domain, which are crucial for cytokine binding. These CHRs are composed of fibronectin type III domains, forming a duplicated ectodomain structure (Sarson-Lawrence2024Cryo-EM). The tertiary structure involves the three-dimensional folding of these domains, allowing for specific interactions with thrombopoietin (Tpo) (Sarson-Lawrence2024Cryo-EM).

In terms of quaternary structure, MPL functions as a homodimeric receptor. Upon binding with Tpo, the receptor dimerizes, which is essential for activating downstream signaling pathways (Sarson-Lawrence2024Cryo-EM). The receptor's intracellular domain interacts with Janus kinases (JAKs), facilitating signal transduction (Varghese2017The).

Post-translational modifications, such as glycosylation, are present in the hinge region of the membrane-proximal CHR, potentially preventing unintended cytokine interactions (Sarson-Lawrence2024Cryo-EM). These structural features are critical for the receptor's function in regulating megakaryocyte and platelet production.

## Function
The MPL gene encodes the thrombopoietin receptor, which is crucial for the regulation of thrombopoiesis, the process of platelet production. This receptor is primarily expressed in hematopoietic tissues, including megakaryocytes, hematopoietic stem cells, and platelets (KAUSHANSKY2009Molecular). Upon binding with thrombopoietin, the receptor undergoes a conformational change that activates JAK family kinases, leading to the phosphorylation of tyrosine residues on the receptor. This creates docking sites for signaling molecules such as STATs, PI3K, and MAPKs, which promote cell survival, proliferation, and differentiation (KAUSHANSKY2009Molecular; Kaushansky2016Thrombopoietin).

The MPL receptor is essential for the survival and expansion of hematopoietic stem cells, as it is one of only two non-redundant hormones affecting these cells (Kaushansky2016Thrombopoietin). It supports the survival and proliferation of CD34+ hematopoietic progenitor cells and is crucial for maintaining quiescent hematopoietic stem cells at the endosteal niche (Hitchcock2014Thrombopoietin). The receptor's signaling is regulated by phosphatases like SHP1, SHIP1, and PTEN, as well as suppressors of cytokine signaling (SOCS), to prevent uncontrolled cell proliferation (KAUSHANSKY2009Molecular). Proper regulation of these pathways is essential for maintaining normal platelet levels and preventing pathologic conditions such as marrow failure or myeloproliferation (KAUSHANSKY2009Molecular).

## Clinical Significance
Mutations in the MPL gene, which encodes the thrombopoietin receptor, are associated with several hematopoietic disorders. These mutations can lead to abnormal cell proliferation and are implicated in conditions such as congenital amegakaryocytic thrombocytopenia (CAMT), hereditary thrombocythaemia (HT), myeloproliferative neoplasms (MPNs), and acute myeloid leukemia (AML) (He2013Different).

Specifically, the MPL W515L and W515K mutations are linked to myelofibrosis, a type of myeloproliferative disorder. These mutations result in cytokine-independent proliferation and constitutive activation of the JAK-STAT signaling pathway, leading to spontaneous megakaryocytic growth and differentiation (Chaligné2007Evidence; Pikman2006MPLW515L). The MPL W515L mutation is found in approximately 5% of JAK2 V617F-negative primary myelofibrosis cases (Guglielmelli2007Anaemia).

Patients with MPL mutations often present with severe anemia and are more likely to be female and older. These mutations are also associated with increased platelet counts and a higher risk of arterial thromboses in essential thrombocythemia (Vannucchi2008Characteristics). The presence of MPL mutations in hematopoietic stem cells suggests a significant role in the pathogenesis of myelofibrosis by affecting hematopoietic differentiation and response to thrombopoietin (Chaligné2007Evidence).

## Interactions
The MPL gene encodes the thrombopoietin receptor, which is involved in several critical protein interactions essential for hematopoiesis. MPL interacts with thrombopoietin (TPO), leading to receptor homodimerization and activation of the JAK2 kinase. This interaction is crucial for initiating signaling pathways such as JAK/STAT, MAPK/ERK, and PI3K/AKT, which are involved in cell proliferation and differentiation (Bhat2018A; Tsutsumi2023Structure).

MPL also associates with various isoforms of the signal transducer and activator of transcription (STAT), including STAT1, STAT3, STAT5A, and STAT5B, which mediate cellular responses to interleukins and growth factors (Alnakhle2023In). Additionally, MPL interacts with calreticulin, a calcium-binding chaperone involved in protein folding, and SHC-transforming protein 1 (SHC1), which links growth factor receptors to signaling pathways (Alnakhle2023In).

Mutations in MPL can lead to constitutive activation of these pathways, contributing to myeloproliferative neoplasms. For instance, the MPL W515 variants and other mutations like MPL S505N result in continuous receptor activation, impacting protein stability and function (Alnakhle2023In). These interactions and mutations highlight MPL's role in hematological diseases and its potential as a therapeutic target.


## References


[1. (Vannucchi2008Characteristics) Alessandro M. Vannucchi, Elisabetta Antonioli, Paola Guglielmelli, Alessandro Pancrazzi, Vittoria Guerini, Giovanni Barosi, Marco Ruggeri, Giorgina Specchia, Francesco Lo-Coco, Federica Delaini, Laura Villani, Silvia Finotto, Emanuele Ammatuna, Renato Alterini, Valentina Carrai, Gloria Capaccioli, Simonetta Di Lollo, Vincenzo Liso, Alessandro Rambaldi, Alberto Bosi, and Tiziano Barbui. Characteristics and clinical correlates of mpl 515w&gt;l/k mutation in essential thrombocythemia. Blood, 112(3):844–847, August 2008. URL: http://dx.doi.org/10.1182/blood-2008-01-135897, doi:10.1182/blood-2008-01-135897. This article has 181 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2008-01-135897)

[2. (Hitchcock2014Thrombopoietin) Ian S. Hitchcock and Kenneth Kaushansky. Thrombopoietin from beginning to end. British Journal of Haematology, 165(2):259–268, February 2014. URL: http://dx.doi.org/10.1111/bjh.12772, doi:10.1111/bjh.12772. This article has 158 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/bjh.12772)

[3. (Alnakhle2023In) Hakeemah H. Al-nakhle, Hind S. Yagoub, Sadin H. Anbarkhan, Ghadah A. Alamri, and Norah M. Alsubaie. In silico evaluation of coding and non-coding nssnps in the thrombopoietin receptor (mpl) proto-oncogene: assessing their influence on protein stability, structure, and function. Current Issues in Molecular Biology, 45(12):9390–9412, November 2023. URL: http://dx.doi.org/10.3390/cimb45120589, doi:10.3390/cimb45120589. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cimb45120589)

[4. (Pikman2006MPLW515L) Yana Pikman, Benjamin H Lee, Thomas Mercher, Elizabeth McDowell, Benjamin L Ebert, Maricel Gozo, Adam Cuker, Gerlinde Wernig, Sandra Moore, Ilene Galinsky, Daniel J DeAngelo, Jennifer J Clark, Stephanie J Lee, Todd R Golub, Martha Wadleigh, D. Gary Gilliland, and Ross L Levine. Mplw515l is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Medicine, 3(7):e270, July 2006. URL: http://dx.doi.org/10.1371/journal.pmed.0030270, doi:10.1371/journal.pmed.0030270. This article has 1119 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.pmed.0030270)

[5. (Tsutsumi2023Structure) Naotaka Tsutsumi, Zahra Masoumi, Sophie C. James, Julie A. Tucker, Hauke Winkelmann, William Grey, Lora K. Picton, Lucie Moss, Steven C. Wilson, Nathanael A. Caveney, Kevin M. Jude, Cornelius Gati, Jacob Piehler, Ian S. Hitchcock, and K. Christopher Garcia. Structure of the thrombopoietin-mpl receptor complex is a blueprint for biasing hematopoiesis. Cell, 186(19):4189-4203.e22, September 2023. URL: http://dx.doi.org/10.1016/j.cell.2023.07.037, doi:10.1016/j.cell.2023.07.037. This article has 9 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cell.2023.07.037)

[6. (Guglielmelli2007Anaemia) Paola Guglielmelli, Alessandro Pancrazzi, Gaetano Bergamaschi, Vittorio Rosti, Laura Villani, Elisabetta Antonioli, Alberto Bosi, Giovanni Barosi, and Alessandro M. Vannucchi. Anaemia characterises patients with myelofibrosis harbouring mplw515l/k mutation. British Journal of Haematology, 137(3):244–247, April 2007. URL: http://dx.doi.org/10.1111/j.1365-2141.2007.06565.x, doi:10.1111/j.1365-2141.2007.06565.x. This article has 120 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/j.1365-2141.2007.06565.x)

[7. (Varghese2017The) Leila N. Varghese, Jean-Philippe Defour, Christian Pecquet, and Stefan N. Constantinescu. The thrombopoietin receptor: structural basis of traffic and activation by ligand, mutations, agonists, and mutated calreticulin. Frontiers in Endocrinology, March 2017. URL: http://dx.doi.org/10.3389/fendo.2017.00059, doi:10.3389/fendo.2017.00059. This article has 54 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2017.00059)

[8. (He2013Different) Xin He, Zhigang Chen, Yangyan Jiang, Xi Qiu, and Xiaoying Zhao. Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases. Journal of Hematology &amp; Oncology, January 2013. URL: http://dx.doi.org/10.1186/1756-8722-6-11, doi:10.1186/1756-8722-6-11. This article has 23 citations.](https://doi.org/10.1186/1756-8722-6-11)

[9. (Kaushansky2016Thrombopoietin) Kenneth Kaushansky. Thrombopoietin and its receptor in normal and neoplastic hematopoiesis. Thrombosis Journal, October 2016. URL: http://dx.doi.org/10.1186/s12959-016-0095-z, doi:10.1186/s12959-016-0095-z. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12959-016-0095-z)

[10. (KAUSHANSKY2009Molecular) K. KAUSHANSKY. Molecular mechanisms of thrombopoietin signaling. Journal of Thrombosis and Haemostasis, 7:235–238, July 2009. URL: http://dx.doi.org/10.1111/j.1538-7836.2009.03419.x, doi:10.1111/j.1538-7836.2009.03419.x. This article has 40 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/j.1538-7836.2009.03419.x)

[11. (Bhat2018A) Firdous A. Bhat, Jayshree Advani, Aafaque Ahmad Khan, Sonali Mohan, Arnab Pal, Harsha Gowda, Prantar Chakrabarti, T. S. Keshava Prasad, and Aditi Chatterjee. A network map of thrombopoietin signaling. Journal of Cell Communication and Signaling, 12(4):737–743, July 2018. URL: http://dx.doi.org/10.1007/s12079-018-0480-4, doi:10.1007/s12079-018-0480-4. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12079-018-0480-4)

[12. (Sarson-Lawrence2024Cryo-EM) Kaiseal T. G. Sarson-Lawrence, Joshua M. Hardy, Josephine Iaria, Dina Stockwell, Kira Behrens, Tamanna Saiyed, Cyrus Tan, Leila Jebeli, Nichollas E. Scott, Toby A. Dite, Nicos A. Nicola, Andrew P. Leis, Jeffrey J. Babon, and Nadia J. Kershaw. Cryo-em structure of the extracellular domain of murine thrombopoietin receptor in complex with thrombopoietin. Nature Communications, February 2024. URL: http://dx.doi.org/10.1038/s41467-024-45356-2, doi:10.1038/s41467-024-45356-2. This article has 1 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-024-45356-2)

[13. (Chaligné2007Evidence) Ronan Chaligné, Chloé James, Carole Tonetti, Rodolphe Besancenot, Jean Pierre Le Couédic, Fanny Fava, Fréderic Mazurier, Isabelle Godin, Karim Maloum, Frédéric Larbret, Yann Lécluse, William Vainchenker, and Stéphane Giraudier. Evidence for mpl w515l/k mutations in hematopoietic stem cells in primitive myelofibrosis. Blood, 110(10):3735–3743, November 2007. URL: http://dx.doi.org/10.1182/blood-2007-05-089003, doi:10.1182/blood-2007-05-089003. This article has 78 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1182/blood-2007-05-089003)